Advertisement

Topics

Companies Related to "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis" [Most Relevant Company Matches] RSS

16:47 EST 14th November 2018 | BioPortfolio

Here are the most relevant search results for "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis" found in our extensive corporate database of over 50,000 company records.

Showing "Alternative Dosing Strategy Ruxolitinib Patients With Myelofibrosis" Companies 1–25 of 4,800+

Relevant

Gofire

Gofire™ is a digital healthcare company developing a proprietary smart inhaler with a personal dosing app that allows patients to re-create consistent experiences, removing the fear of taking too much while having the support of their community to help find products best suited to specific ailments. Gofire is committed to making alternative health acc...


Impact Biomedicines

Impact Biomedicines (“Impact”) is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule, JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera ...

Tapestry Pharmaceuticals

Tapestry Pharmaceuticals, Inc. is a company focused on developing proprietary therapies for the treatment of cancer. We are also actively engaged in evaluating new therapeutic agents and related technologies for in-licensing. Tapestry's technical expertise is our ability to identify, chemically alter and produce novel therapeutic compounds derived from natural product sources. Tapestry has devel...


TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis...

Glytec

Founded in 2006, Glytec is a rapidly growing clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control. The eGlycemic Management System™ (eGMS™) enables hospitals and healthcare systems to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia and of...

Microchips Biotech Inc.

Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. The company’s proprietary platform technology is a microchip-based implant which can store and release precise doses of drugs at scheduled intervals for up to 16 years. The microchip-based implant has the potential to address significant unmet ne...

Microchips Biotech, Inc.

Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. The company’s proprietary platform technology is a microchip-based implant which can store and release precise doses of drugs at scheduled intervals for up to 16 years. The microchip-based implant has the potential to address significant unmet ne...

Glytec, LLC

Founded in 2006, Glytec is a rapidly growing clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control. The eGlycemic Management System™ (eGMS™) enables hospitals and healthcare systems to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia and of...

ConjuChem Incorporated

ConjuChem Inc. is a biotechnology company that has developed proprietary technology that enable the rapid creation of improved patentable new drugs from existing drugs.The new drugs will have similar therapeutic activity but with duration of activity in the body that allows for once or twice per month dosing as compared to the multiple daily dosing required of the original.

Neulasta® (pegfilgrastim)

Neulasta® (pegfilgrastim) is approved for once-per-cycle dosing to decrease the incidence of infection (as manifested by febrile neutropenia)in certain cancer patients who are receiving chemotherapy.

Mellitus Health

Founded in 2014 as Insulin Algorithms by Mayer Davidson, MD, Josh Davidson and Michael Margolese, the Los Angeles firm rebranded in 2018 as Mellitus Health, Inc. Its cloud-based insulin titration software works with all insulins and combinations and all 125 dosing regimens, providing precision insulin dosing recommendations to clinicians in just seconds. T...

Cyclacel Limited

Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; CYC400), Penetratin®-small molecule complexes (CYC300), Pimetic™ small molecules mimicking natural cancer suppressing genes (CYC100), and intelligent delivery and targeting systems (Penetratin® an...

Imago BioSciences

Imago BioSciences is a clinical-stage, venture-backed pharmaceutical company focused on improving the management of proliferative diseases of the bone marrow and modulation of the immune system. The company is currently focused on neoplastic diseases of the bone marrow including acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibr...

Innovative Detox

Innovative Detox was created by four medical professionals to offer people addicted to alcohol or prescription painkillers a medically-sound alternative to traditional rehab. That can take a month or more to get their patients through withdrawal – followed by a lifetime of struggle to remain addiction-free by force of will – which produces a 75 percent ...

TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www...

BioRexis Pharmaceutical Corporation

BioRexis™ develops and produces novel biopharmaceuticals with superior pharmacology using efficient manufacturing systems. Many biopharmaceuticals face difficulties in development and commercialization due to pharmacological issues. For example, many peptides that are currently approved or in development have a very short half-life, requiring both high and frequent dosing. Unwanted side effects ...

Dr. Delany

Dr. Delany is a multiple board certified ( Internal Medicine, Cardiology, Critical Care, and Geriatrics) integrative medical physician who has been in the private practice of medicine for over 20 years in Milton, Massachusetts. Dr. Delany has specialized training in both Anti-Aging and Functional Medicine. He is a caring physician, an excellent lecturer, and an experienced cardiology and integra...

Compassionate Organics, LLC

Compassionate Organics, LLC (CO) was founded in 2011 by Geoffrey Reilinger, a longtime Back Bay resident who was diagnosed with Multiple Sclerosis in 1996 and has used medical marijuana (MM) with incredible results. CO is a registered Massachusetts domestic for-profit corporation whose mission is to provide safe, confidential access to high-quality MM for ...

Bristol-Myers Squibb and TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www....

Debiopharm Group

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect on HCV replication both in vitro and in vivo. Debio 025 has excellent antiviral activity against a broad range of genotypes (1, 2, 3 and 4); a high barrier to the development of resistance; and the pos...

Probably Relevant

Alternative Health Networks, Inc

Our Mission: Alternative Health Networks is dedicated to providing premium quality natural health products to all our customers. We maintain a conservationist view of botanical usage and promote the ethological and sustainable use of rare herbs in all our processing. Renewable botanicals and increased biodiversity have always been in the forefront of our company's philosophy.History: Alternative H...

CAM Research Institute

Our organization strives to conduct research, both clinical and non-clinical, for promising but unproven alternative and complementary therapies for a variety of conditions. The research we conduct will adhere to the highest standards of health care research to determine whether an alternative therapy is safe and effective or potentially dangerous and ineffective. To educate both the public and he...

Institute for Alternative Futures

The Institute for Alternative Futures (IAF) is a non-profit research and educational organization formed in 1977 by futurists Clement Bezold, Alvin Toffler and James Dator. Drawing on futures methodologies, IAF helps organizations explore future possibilities and create the futures they prefer.

ExonHit Therapeutics SA

ExonHit is the world's leader in the analysis of alternative splicing. Alternative RNA splicing is an essential, naturally occurring biological process in which a single gene directs the production of several proteins. Abnormal alternative RNA splicing events can lead to the production of proteins that may trigger or contribute to the onset of various diseases.

The Bruckner Group

The Bruckner Group (www.brucknergroup.com) is a strategy consulting company that assists biopharmaceutical and device executives on a wide variety of new product development and product commercialization strategic issues. Bruckner is the industry pioneer of healthcare value strategy, and a leading expert and thought leader in payer strategy, and value prop...


More From BioPortfolio on "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks